Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Experts are rethinking the playbook for advanced prostate cancer, with genomic testing now guiding upfront treatment choices rather than just informing later lines. At an OncLive workshop, oncologists and urologists debated when to intensify therapy, how to sequence radioligand treatments, and which patients truly benefit from chemotherapy triplets — all while keeping an eye on toxicity and real-world access.
The treatment landscape for advanced prostate cancer is getting more complex — and more personalized. At a recent OncLive Scientific Interchange and Workshop, a panel of oncologists and urologists discussed how genomic testing, biomarker-directed combinations, and radioligand therapies are reshaping decision-making from the very first treatment choice onward.
A key theme: genomic results should inform initial therapy, not just later lines. Many clinicians now wait for next-generation sequencing before selecting an androgen receptor pathway inhibitor (ARPI). For patients with BRCA2 mutations, the FDA-approved niraparib + abiraterone combo (Akeega) offers a meaningful rPFS benefit. Meanwhile, docetaxel triplets are reserved for younger, fitter patients with high-volume disease — though no head-to-head data yet proves triplets beat ARPI doublets.
On radioligand therapy (lutetium-177 PSMA), the panel was split: some favor earlier use to ensure patients benefit before resistance sets in, while others worry about marrow toxicity in patients who may live for years.
Key Takeaways:
Why it matters: As more targeted options emerge, the challenge isn't just efficacy — it's matching the right therapy to the right patient while managing toxicity, logistics, and access barriers.
